With weight loss drugs taking the world by storm, more people are exploring adding these medical marvels to their toolkits.

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

Welcome to The Thin Line, The New York Post’s new series about the darker side of GLP-1 drugs. Though GLP-1 agonists sold ...

New weight-loss drugs in the works will offer more choices beyond GLP-1 options Wegovy and Zepbound. What to know about ...

Meals and snacks with "GLP-1 Friendly" labels on the packaging are becoming more common as a growing number of Americans try ...

The GLP-1 moment signals how quickly a high-demand therapy can upend established care patterns—and how similar innovations ...

GLP‑1 weight‑loss drugs are reshaping food industry demand, but side effects, cost barriers and unclear long‑term impacts ...

As GLP-1 medications normalize smaller appetites and higher protein intake, national restaurant chains are quietly ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco.

As the GLP-1 trend expands, a 'halo effect' is developing. Consumers in families of GLP-1 users are increasingly eating GLP-1 ...

As many as 12% of Americans are currently using GLP-1 medications such as Ozempic and Wegovy, according to one estimate.

At a high level these drugs mimic glucagon-like peptide-1, or GLP-1, a hormone our bodies naturally produce in the gut. When ...